Milestone Scientific Announces Appointment of Eric Gilbert as Vice President of US Sales

LIVINGSTON, NJ -- (Marketwired) -- 04/10/18 -- Milestone Scientific Inc. (NYSE American: MLSS) (NYSE MKT: MLSS), a leading developer of computerized drug instruments that provide painless and precise injections, today announced the appointment of Eric W. Gilbert as Vice President of US Sales.

Eric Gilbert brings extensive experience in medical instruments sales, including extensive experience with leading anesthesiologists and radiologists, as well as orthopedic and neuro surgeons. Prior to joining Milestone Scientific, he served as Vice President of Sales for Osseon, Inc., a worldwide manufacturer and distributor of novel spinal instruments, where he managed independent and direct sales channels and was responsible for a strong turnaround and return to growth. Previously, he served as Vice President of Sales and Marketing for Benvenue Medical, Inc, where he was responsible for the company's US commercial field operations. He also worked with Ascendx Spine, Inc, where he helped secure 510(K) marketing clearance with the FDA and drafted the post-market study protocol.

Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, commented, "We are pleased to announce the appointment of Eric Gilbert as our VP of US sales, which follows our recent appointment of Sharon Smith as EVP of Global Sales & Marketing. Our immediate focus is accelerating the commercial roll-out of our CompuFlo® Epidural Computer Controlled Anesthesia System by establishing relationships with key opinion leaders and partnering with US distributors. We believe Eric is ideally suited to lead our domestic expansion initiatives, given his successful track record within the medical device arena, including the anesthesia and orthopedic specialties."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation instruments, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website:www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are our inability to raise capital when needed which may force us to delay, curtail or eliminate commercialization efforts of our CompuFlo® Epidural Computer Controlled Anesthesia System, reliance on informal arrangements with third parties to manufacture our products, maintenance of product quality, product acceptance and use by physicians, developments by competitors, inability to defend our patent, adverse patent rulings, the extent to which reimbursement will be available, FDA or legal developments, general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, , changes in customer and market requirements and standards, and the other risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

Source: Milestone Scientific, Inc.